Innovators Pop-Up was born out of the idea that early innovators need a space dedicated to showcasing their technology that allows for connection with key industry influencers, provides a compelling and memorable experience for attendees, and delivers enduring impact.
Innovators Pop-Up was born out of the idea that early innovators need a space dedicated to showcasing their technology that allows for connection with key industry influencers, provides a compelling and memorable experience for attendees, and delivers enduring impact.
6:00–9:00 PM EST | 16 October 2025
Cuba Libre Restaurant & Rum Bar
This dynamic and immersive event will showcase cutting-edge healthcare innovations in an interactive “playground.” Dive into a world where groundbreaking ophthalmology meets hands-on exploration, fostering connections and sparking revolutionary ideas.
Get HANDS-ON with the
latest technologies in
ophthalmology
Connect with industry
leaders and fellow
visionaries
Be part of shaping the
next wave of ophthalmic
advancements
Pop into our exclusive email list and be the first to know where Innovators Pop-Up will pop up next. It’s like a surprise party for your inbox – but way cooler.
eyejourney by Innoptix streamlines the patient journey by automating reminders, checklists, and medication tracking, improving patient engagement while delivering valuable benefits for clinics.
At Greenman, we are transforming cataract education using cutting edge technology. By turning complex medical decisions into clear, experience-driven choices, we’re empowering patients to take control of their vision health with confidence and strengthening surgeon-patient communication by fostering informed dialogue.
Our virtual reality technology, the InSightVR system, allows patients to visualize their post-surgical outcomes before making a decision. This sets realistic expectations, improves decision-making, and fosters trust.
Sydnexis is a a privately-held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently awaiting PDUFA approval at FDA for its patented eyedrop formulation, SYD-101, a low-dose atropine eye drop engineered specifically for growing eyes. It is being studied in children as young as 3 as a potential pharmaceutical treatment for progressive pediatric myopia. Our landmark STAR study — the largest and most comprehensive of its kind — has generated rigorous long-term data to help establish a safe, consistent solution to one of the most urgent unmet needs in pediatric ophthalmology.
At TECLens, we’re dedicated to restoring vision and improving quality of life for millions of people around the world.
Our innovative treatment utilizes proprietary quantitative corneal cross-linking (qCXL™) technology and the CXLens® device to gently strengthen and reshape the cornea, designed to redefine vision correction for refractive errors, including restoring near vision for those with presbyopia. The procedure aims to be a comfortable, non-invasive, in-office treatments.
TECLens is also exploring future applications for hyperopia, progressive myopia in children and low-order myopia in adults, and keratoconus, promising a brighter future for vision correction.
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
True North Contract Research is a dynamic and rapidly growing Contract Research Organization (CRO) specializing in Ophthalmology research. We strive to deliver an experience that is second to none to our sponsor partners and site partners. Our longstanding commitment to advancing the field of ophthalmology through clinical research has provided us with the experience to execute trials efficiently with a focus on accuracy and compliance. We merge FDA and clinical site perspectives to identify effective solutions that are agreeable to both parties and then mitigate roadblocks to achieve trial endpoints. One of our greatest strengths is uniting with sponsoring companies as a seamless team that makes well-thought-through decisions on time.
Amaros’ EvidenceEngine™ is an AI-powered platform designed to unify and transform fragmented ophthalmic data into actionable intelligence, revolutionizing clinical development, research, and therapeutic decision-making across the eye care continuum. Built in Silicon Valley and backed by serial ophthalmic entrepreneurs, AI scientists, clinicians, and CRO experts, the platform targets a critical bottleneck in ophthalmology: disconnected datasets that hinder efficient trials, slow adoption of therapies, and limit patient access.
Market Scope is the leading source for market intelligence in ophthalmology. We’ve been focusing on the global ophthalmic market since 1996, performing syndicated and primary market research and embedding ourselves in the field. Whether you are looking to launch a product, considering a merger or acquisition, investing, working on research and product development, or strategic planning, we can get the data you need. Because better data means better decisions.
Lelu Management is a dedicated service provider specializing in healthcare solutions. Our focus is on empowering healthcare organizations with innovative strategies that streamline operations, enhance financial management, and optimize overall efficiency. We partner with industry leaders to offer tailored solutions that meet the unique needs of the healthcare sector, ensuring our clients can focus on delivering high-quality patient care while we handle the rest.